Suggested remit: To appraise the clinical and cost effectiveness of upadacitinib within its marketing authorisation for treating active psoriatic arthritis.
 
Status Proposed
Process STA 2018
ID number 2690

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
12 June 2020 - 10 July 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance